Fondaparinux
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Fondaparinux
Fondaparinux: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Fondaparinux, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 4 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| myocardial infarction | licence in another country |
| pulmonary embolism | licence in another country |
| unstable angina | licence in another country |
| venous thrombosis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 8775W | Arixtra | Injection containing fondaparinux sodium | Valid |
Safety Considerations
Contraindications suggested by the knowledge graph (these come from drug-disease relationship data, not from approved label text):
- Heparin-induced thrombocytopenia
- Thrombocytopenia, including immune thrombocytopenia
- Blood coagulation disease
- Kidney disease
- Anaemia, including macrocytic anaemia
- Endocarditis, including subacute bacterial endocarditis
- Diabetic retinopathy and diabetic cataract
- Pyoureter
Several of these (thrombocytopenia, coagulation disorders, retinal vascular disease) overlap directly with the predicted indications and reinforce the bleeding-risk concern.
Drug Interactions: The interaction screen returned 100 interactions in total. Examples of those rated Major include:
- Acetylsalicylic acid (aspirin)
- Ibuprofen
- Ketorolac
- Abciximab
- Acalabrutinib
- Anagrelide
- Antithrombin alfa and antithrombin III human
- Deferasirox
- Trastuzumab emtansine
- Ibritumomab tiuxetan and tositumomab
Most of these combinations raise bleeding risk. Moderate-level examples include fenfluramine, dexfenfluramine, sibutramine, sugammadex and radioiodine products.
Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications, because label-level safety data were not available for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.